 Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Shocked!

J Clin Oncol: Shocked!

 Last Update: 2021-05-08
 Source: Internet
 Author: User

Tags

manufacturing time study

pulmonary cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Esophageal cancer is a common medsci.

medsci.

According to the principle of radiotherapy and chemotherapy followed by surgery for esophageal cancer, preoperative radiotherapy and chemotherapy have become the standard treatment for patients with locally advanced resectable esophageal cancer or borderline cancer.

From 2004 to 2008, researchers randomly divided 366 patients into two groups and received carboplatin + paclitaxel (5 weeks/course) combined with radiotherapy (5 days a week, 23 times, total 41.

Overall survival rate

The median follow-up time was 147 months (interquartile range: 134-157).

The overall survival rate of patients receiving neoadjuvant chemoradiation is higher (hazard ratio [HR] 0.

Cumulative mortality from different causes

The 10-year absolute overall survival benefit is 13% (38% vs 25%) .

The 10-year absolute overall survival benefit is 13% (38% vs 25%)

Cumulative recurrence rate

Although it has a significant impact on isolated local recurrence (HR 0.

In short, according to the CROSS criteria, the overall survival benefit of patients with locally advanced resectable esophageal cancer or borderline cancer from preoperative radiotherapy and chemotherapy can last at least 10 years!

According to the CROSS criteria, the overall survival benefit of patients with locally advanced resectable esophageal cancer or borderline cancer from preoperative radiotherapy and chemotherapy can last at least 10 years! According to the CROSS criteria, the overall survival benefit of patients with locally advanced resectable esophageal cancer or borderline cancer from preoperative radiotherapy and chemotherapy can last at least 10 years!

Original source:

Eyck Ben M, van Lanschot J Jan B, Hulshof Maarten CCM et al.

org/10.
1200/JCO.
20.
03614" target="_blank" rel="noopener">Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gefitinib

CAS No.: 184475-35-2

Pharmacy Grade

$1/MT FOB

High quality Sunitinib CAS NO 557795-19-4 Orange solid powder 99% API for antitumor

CAS No.: 557795-19-4

Pharmacy Grade

$4.1-4.2/G FOB

Epirubicin

CAS No.: 56420-45-2

$1/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.